TORONTO and RIONEGRO,
Colombia, June 21, 2019 /CNW/ - PharmaCielo
Ltd. ("PharmaCielo" or the "Company")
(TSXV:PCLO) (OTC:PHCEF), the Canadian parent of
Colombia's premier cultivator and
producer of medicinal-grade cannabis oil, PharmaCielo Colombia
Holdings S.A.S., is pleased to announce that it is trading on the
OTC Markets under the symbol "PHCEF".
"With our recently announced acquisition agreement with Creso
Pharma (ASX:CPH) there is increased attention and interest in our
stock. Trading on the OTC will increase access for U.S. and
international investors, providing greater liquidity and better
access to capital. As we move forward building a global medicinal
cannabis company, we will work to provide easy access and liquidity
for investors in all jurisdictions," said David Attard, Chief Executive Officer of
PharmaCielo Ltd.
About PharmaCielo
PharmaCielo Ltd. (TSXV:PCLO)
(OTC:PHCEF) is a global company, headquartered in Canada, with a focus on ethical and
sustainable processing and supplying of all natural,
medicinal-grade cannabis oil extracts and related products to large
channel distributors. PharmaCielo's principal (and wholly owned)
subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered
at its nursery and propagation centre located in Rionegro,
Colombia.
The boards of directors and executive teams of both PharmaCielo
and PharmaCielo Colombia Holdings are comprised of a diversely
talented group of international business executives and specialists
with relevant and varied expertise. PharmaCielo recognized the
significant role that Colombia's
ideal location will play in building a sustainable business in the
medical cannabis industry, and the Company, together with its
directors and executives, is executing on a business plan focused
on supplying the international marketplace.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements can be identified by the use of words
such as, "expects", "is expected", "intends", "believes", or
variations of such words and phrases or state that certain actions,
events or results "may" or "will" be taken, occur or be achieved.
Forward-looking statements are based on assumptions, including with
respect to PharmaCielo's planned products, and the ability to
execute its business plan that management believes are reasonable
in the circumstances, but the actual results, performance or
achievements of PharmaCielo's business may be materially different
from any future results, performance or achievements expressed or
implied by any forward-looking statements. Forward-looking
statements can be affected by known and unknown risks,
uncertainties and other factors, including, but not limited to, the
equity markets generally, risks associated with early stage
companies, risks associated with the regulation of cannabis and
cannabinoid derivatives, failure to obtain necessary TSXV approval,
competition for PharmaCielo's planned products, risks associated
with operating in Colombia, and
currency exchange risk. Accordingly, readers should not place undue
reliance on forward-looking statements.
Except as required by law, PharmaCielo undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
SOURCE PharmaCielo Ltd.